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Early detection of treatment response by diffusion-weighted 'H-NMR
spectroscopy in a murine tumour in vivo
M Zhao', JG Pipe2, J Bonnett' and JL Evelhoch" 2
Departments of 'Internal Medicine and 2Radiology, Wayne State University School ofMedicine, Detroit, Michigan 48201, USA.
Summary Nuclear magnetic resonance (NMR) non-invasively measures the apparent diffusion coefficient
(ADC) of water, which is sensitive to the biophysical characteristics of tissue. Because anti-cancer treatment
alters tumour pathophysiology, tumour ADC may be altered by treatment. In order to test this hypothesis,
ADC was measured in s.c. implanted murine RIF-I tumours before and up to 9 days after treatment with
cyclophosphamide. A dose-dependent, reversible increase in tumour ADC was observed after cyclophos-
phamide treatment, which is consistent with an increase in the fraction of interstitial water due to treatment-
induced cell death. Because tumour water ADC is increased substantially at a time when there is no change in
tumour volume for a dose which produces minimal cell kill, its measurement could provide a novel means for
early detection of response to anti-cancer therapy. If the changes in ADC observed in the present study are
evident for commonly used anti-cancer therapies in different tumour types and specific to a therapeutic
response, this approach could be broadly applicable as a response predictor since magnetic resonance imaging
can be used to measure ADC in human tumours.
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The response of human malignancies to commonly used
therapy varies markedly even for patients with tumours of
the same tissue of origin, stage and classification. Clinical
detection of therapeutic efficacy (generally a 50% decrease in
tumour volume assessed radiographically) is seldom possible
early in the course of treatment when the information could
be used to tailor therapy for individual patients. Thus, the
need for early predictors of tumour responsiveness to com-
monly used therapeutic modalities has long been recognised.
The ability to predict therapeutic response in individual
patients after an initial (or 'test') dose of a fraction of the
maximum tolerated dosage would both allow patients with
non-responsive tumours to avoid the side-effects and tox-
icities of a full course of therapy and aid in the selection of
patients for the clinical trials of new anti-tumour therapies.
One approach being evaluated as a response predictor is to
assess tumours before and during treatment in an attempt to
detect changes in the pathophysiology of tumours responding
to the initial therapy. Non-invasive methods, including
magnetic resonance spectroscopy (e.g. Koutcher et al., 1990;
Presant et al., 1994; Sostman et al., 1994) and positron
emission tomography (e.g. Ichiya et al., 1991; Wahl et al.,
1993; Berlangieri et al., 1994), are being evaluated for their
ability to provide such information. While the initial results
using these approaches are encouraging, their ultimate utility
remains to be established. Potential weaknesses of these app-
roaches are their limited sensitivity to therapeutic response
and coarse spatial resolution. Ideally, one would like to be
able to detect the changes associated with a small therapeutic
effect at the highest possible spatial resolution. This would
both permit intra-tumour heterogeneity to be assessed and
allow the smallest possible 'test' dose to be used to identify
patients with non-responsive tumours. Although magnetic
resonance imaging (MRI) has the spatial resolution needed
to assess macroscopic heterogeneity, treatment-induced chan-
ges in relaxation times have been reported only for ex vivo
measurements (Braunschweiger et al., 1986; Belfi et al., 1991)
and they may not provide sufficient sensitivity to serve as
response predictors. However, recent reports of the ability of
MRI to detect changes in brain water diffusion associated
with pathophysiological changes occurring as a result of
cerebral ischaemia (Mosely et al., 1990; Warach et al., 1992),
status epilepticus (Zhong et al., 1993) or spreading cortical
depression (Latour et al., 1994a) indicate that diffusion
measurements may provide greater sensitivity to changes in
tumour pathophysiology in response to treatment.
Water diffusion measured by pulsed-field gradient nuclear
magnetic resonance (NMR; Stejskal and Tanner, 1965) is
influenced by the restriction of diffusion due to the limited
permeability of cell membranes to water (Cooper et al.,
1974). Hence, the water diffusion coefficient measured by
NMR is referred to as the apparent diffusion coefficient
(ADC) and it is sensitive to the biophysical characteristics of
tissue, including the fraction of water in the extracellular
space (Latour et al., 1994b). Because both radiation (Peterson
et al., 1976) and chemotherapy (Braunschweiger, 1988) sub-
stantially increase the fraction of extracellular water, tumour
water ADC may be altered by treatment. If therapy causes a
change in tumour water ADC, it could provide a clinically
applicable therapeutic response predictor because MRI of
water diffusion can be applied to human tumours (Le Bihan
et al., 1986; Brunberg et al., 1995). Consequently, in an effort
to determine if treatment-induced changes in tumour
pathophysiology alter tumour water ADC before a
significant decrease in tumour size, ADC was measured in
s.c. implanted murine radiation-induced fibrosarcoma 1
(RIF-1) tumours before and up to 9 days after treatment
with cyclophosphamide (CP; 150 mg kg-1 or 300 mg kg-').
Materials and methods
Murine tumour model
The RIF-1 originally obtained from RF.Kallman (Stanford
University) was maintained by serial in vivo-in vitro passage
as described by Twentyman et al. (1980). Tumours were
implanted in female C3H/HeJ mice (Harlan Sprague-Dawley,
Indianapolis, IN, USA) by s.c. injecting 105 cultured cells in
0.1 ml of medium into the shaved back of the animal about
2 cm from the tail base. Tumour sizes were estimated by
calculating the volume of an ellipsoid V = (it/6)abc where a,
b, and c are three perpendicular axes determined from caliper
measurements. When tumours reached 200-600 mm3, mice
were distributed into one of three treatment groups: control
(no treatment); 150 mg kg-' CP; or 300 mg kg-' CP. After
NMR measurement of tumour ADC (day 0), mice in the CP
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treatment groups received an i.p. injection of freshly prepared
CP in 0.2 ml of sterile water. Tumour response to treatment
was estimated by the tumour growth delay (TGD, i.e. median
time for treated tumours to double in size minus the median
time for control tumours to double in size; Corbett and
Valeriote, 1987).
NMR measurements
NMR spectra were acquired on a Bruker Biospec II spect-
rometer equipped with a 4.7-T horizontal-bore magnet and
actively shielded gradients. During NMR observation, the
mouse was anaesthetised (1% v/v halothane) and immo-
bilised on a bed that was heated by circulating temperature-
controlled water. A thermocouple was inserted rectally to
monitor mouse core temperature (36.5 ± 0.5°C). The tumour
was isolated from the mouse body using a copper shield with
a variable diameter hole to minimise signal contamination
from normal tissue. Diffusion-weighted 'H-NMR spectra
were acquired using a pulsed-field gradient, stimulated echo
(PFGSTE) pulse sequence (Tanner, 1970). Four single-
acquisition echoes were acquired for each b-factor using a
repetition time of 10 s to avoid saturation effects. The
diffusion-weighted b-factor (b =y2G232 (A-3/3)) was varied
by changing the diffusion gradient strength (G) from 10 to
30 mT m ', while the duration of the diffusion gradient (6)
and the gradient separation time (A) were held constant at
10ms and 200 ms respectively. The anisotropy of tumour
ADC was tested by repeating the measurements in six un-
treated tumours using the x, y, or z gradient as the diffusion
gradient.
Data analysis
For a given b-factor, each of the single acquisition echoes
were baseline-corrected, zero-filled, Fourier-transformed, and
magnitude spectra were calculated. The water PFGSTE amp-
litudes were measured as peak heights from the four mag-
nitude spectra and the amplitudes were averaged to avoid
phase-related motion artifacts. Model fitting and statistical
analyses were performed using CSS:STATISTICA/w (Stat-
Soft, Tulsa, OK, USA). Tumour ADC was estimated by
non-linear least squares fitting (Quasi-Newton Algorithm) of
the PFGSTE amplitude as a function of the diffusion-
weighting b-factor to the Stejskal-Tanner formula (Stejskal
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Figure 1 Representative semi-log plots of RIF-I tumour water
PFGSTE amplitudes (arbitrary units) as a function of the
diffusion-weighting b-factor. Symbols are measured amplitudes
for: *, control tumour, ADC =0.41 ± 0.01 x 109m2s-' (s.e.
estimated from fit); *, tumour 4 days after 150mgkg-' CP,
ADC = 0.61 ± 0.02 x l109m2 s-'; and 0, tumour 4 days after
300mg kg-' CP, ADC = 0.83 ± 0.02 x 10-9m2 s-'. The lines
correspond to non-linear least squares fits of these data to the
Stejskal-Tanner formula.
and Tanner, 1965), which relates the echo amplitude for a
given b-factor (Ab) to ADC; Ab = AO x exp (- b x ADC).
Statistics
Two dependent variables measured across time were analy-
sed: tumour size and tumour ADC. Both variables were
measured five times in mice in the no treatment group (days
0, 1, 2, 3 and 4) and eight times in mice in the CP treatment
groups (before treatment and days 1-4 and 7-9 after treat-
ment). For both variables, the following analyses were per-
formed. First, a repeated measures two-factor (time, treat-
ment group) analysis of variance (ANOVA) using Geisser-
Greenhouse-corrected P-values was performed (Kirk, 1982).
When a statistically significant interaction was detected
between treatment group and time, a repeated measures
ANOVA was performed to test for change over time in each
treatment group. If a significant change over time was
detected, a Tukey test (Zar, 1984) was performed to deter-
mine at which time points the value differed from the pre-
treatment (day 0) value. A repeated measures two-factor
(time, treatment group) ANOVA using Geisser-Greenhouse-
corrected P-values was also performed for the data from the
two CP treatment groups. When a statistically significant
interaction was detected between the CP dose and time, a
Tukey test was performed to determine at which time points
the value differed between the CP doses.
Results
The ADC of tap water in a flask at 20 ± 1°C was measured
by the PFGSTE pulse sequence to be 2.15 ± 0.02 (10-9
m2s-'), which is consistent with the literature value (Mer-
boldt et al., 1985). Figure 1 shows representative PFGSTE
data from which tumour water ADC was determined for a
control (no treatment) RIF-1 tumour and for RIF-1 tumours
4 days after a single dose of either 150 mg kg-' or
300 mg kg-' CP. The tumour water PFGSTE amplitudes as
a function of the diffusion-weighting b-factor were fitted to
the Stejskal-Tanner formula (Stejskal and Tanner, 1965) to
derive tumour ADC: these ranged from 0.33 x 10-9 m2 s-' to
0.96 x 10-9m2 s' in all measurements. The maximum
difference between tumour ADC measured with the diffusion
gradient oriented along the x, y or z-axis of the magnetic
field was ± 0.01 x 10-9m2 s' in six tumours. Consequently,
tumour ADC is isotropic in RIF-I tumours.
The time and dose dependence of the size of RIF-I
tumours treated with CP is presented in Figure 2. The pat-
tern of changes over time in tumour size differed among the
treatment groups (control, 150 mgkg-' CP and 300 mg kg-'
CP) over the first four days of observation (two-factor
repeated measures ANOVA; P<0.00001 for the interaction
between time and dose). In control tumours the size in-
creased significantly over 4 days of observation (repeated
measures ANOVA; P= 0.0004). The tumour size increased
significantly compared with the day 0 size on days 2-4
(Tukey test; P<0.001 for all days). Although tumour size
did not change significantly over time after treatment with
150mgkg-' CP (P>0.1), treatment with 300mgkg-' did
significantly change tumour size (P<0.00005). Tumour size
decreased significantly compared with the pretreatment value
on days 3 and 4 after a single dose of 300 mg kg-' CP,
(P<0.0002 for both days) and returned to a size not
significantly different from the pretreatment size by day 7.
The effect of CP on tumour size did not differ significantly
between the two CP treatment groups (P>0.1).
The time and dose dependence of the ADC in RIF-I
tumours treated with CP is presented in Figure 3. The pat-
tern ofchanges over time in tumour ADC differed among the
treatment groups (P<0.00001 for the interaction between
time and dose) over the first 4 days of observation. In control
tumours, ADC did not change (P>0.6) over 4 days of
observation. However, over time after treatment with either
150 mg kg-' CP or 300 mg kg-' CP, tumour ADC changedDiffusion-weighted 'H-NMR response detection
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Figure 2 Time and dose dependence of the effect of CP on
RIF-1 size (relative to size on day 0 for each tumour): *, control
[no treatment; n = 6, mean tumour size on day 0 (size
0) = 525 ± 80 (s.e.) mm3]; *, 150 mg kg- CP (n = 6, sizeo =
385 ± 45 mm3); *, 300 mg kg- CP (n = 6, sizeo = 451 ± 46 mm3).
Sizeo did not differ among groups (univariate ANOVA, P = 0.2).
Symbols represent mean ± s.e. (bars); +, significant difference
from the day 0 size.
significantly (P<0.0005 for both). Tumour ADC
significantly increased compared with the pretreatment (day
0) value on days 2-4 after a single dose of 150 mg kg-' CP
(P<0.0002 for all days). After a single dose of 300 mg kg-'
CP, tumour ADC increased significantly compared with the
pretreatment value from day 2 to day 9 post treatment
(P<0.005 for all days). The effect of CP on tumour ADC
differed significantly between the two CP treatment groups
(P<0.002). Tumour ADC was higher from days 3 -8
(P<0.05 for all days) in mice treated with 300 mg kg' CP
than in mice treated with 150 mg kg-' CP.
Discussion
The principal aim of this study was to determine whether
non-invasive measurement of tumour ADC via NMR can
detect changes in tumour pathophysiology in response to
chemotherapy. These initial results show that ADC is rever-
sibly altered by CP in RIF-1 tumours in the absence of or
before decreases in tumour volume. The magnitude and
duration of the changes in ADC are dose dependent:
300mgkg-' CP provokes a larger, more sustained increase
in ADC than does 150mgkg-' CP.
The model recently introduced by Latour et al. (1994b) for
diffusion of water in biological systems provides a framework
to consider how treatment-induced changes in tumour
pathophysiology could account for the changes observed in
ADC. This model considers the tissue water existing in two
compartments, intra- or extracellular. The variables in the
model are the diffusion coefficient and fractional water con-
centration (vol/vol; due to the fractional concentration
occupied by macromolecules) of both compartments, the
fraction of extracellular water and the radius and membrane
permeability of the cells, which are modelled as spheres. For
tumours in vivo, there is a third component from water in the
blood. However, since blood occupies less than 5% of RIF-l
volume (Braunschweiger, 1988) and the water in blood has a
greater apparent diffusion coefficient due to the effect of
perfusion (at least ten times greater than ADC in brain; Le
Bihan et al., 1986), the vascular contribution should be
minimal over the range of diffusion-weighting b-factors used
in this study (0.1-2.6 x I0-9 smi-2). Thus, ADC measured in
RIF-1 tumours should predominantly reflect intracellular and
extracellular, extravascular (i.e. interstitial) water. According
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Figure 3 Time and dose dependence of the effect of CP on
RIF-1 ADC (relative to ADC on day 0 for each tumour): *,
control [n = 6, mean tumour ADC on day 0 (ADCO) =
0.42±0.04x 10-9m2s- ]; *, l50mgkg-' CP (n=6, ADCo=
0.40 ± 0.01 x 10-9m2s- ); 0, 300mgkg-' CP (n = 6, ADCo
= 0.42 ± 0.01 x 10-9m2 s-'). ADCo did not differ among groups
(P = 0.8). Symbols represent mean ± s.e. (bars); +, significant
difference from the day 0 size; *significant difference between the
150 mg kg-' and 300 mg kg- groups; (- ), pretreatment
(day 0) ADC.
to the model of Latour et al. (1994b) an increase in RIF-l
ADC would occur if: (i) the interstitial diffusion constant
increased; (ii) the cell radius increased; (iii) the intracellular
fractional water concentration decreased; (iv) the interstitial
fractional water concentration increased; (v) the fraction of
interstitial water increased; or (vi) the membrane perm-
eability increased. Thus, the 70-100% increase in the frac-
tion of interstitial water measured by radiotracers in RIF-I
tumours 2-5 days after treatment with 150 mg kg-' CP
(Braunschweiger, 1988) may account, at least in part, for the
changes in ADC observed in the present study. Moreover,
the decrease in ADC toward the pretreatment value by the
7th day after treatment with 150mgkg-' CP parallels that
observed by Braunschweiger (1988). The larger and more
prolonged increase in ADC after 300 mg kg-' CP would be
expected for a greater increase in interstitial water space due
to greater cell kill at the higher dose. However, without
explicit knowledge of the effects of CP on the remaining
variables in the model, it is not possible to determine whether
changes in the fraction of interstitial water could account
entirely for the observed changes in ADC.
Because MRI can measure ADC in human tumours with
spatial resolution, which should aid in evaluating hetero-
geneity (Le Bihan et al., 1986; Brunberg et al., 1995),
treatment-induced changes in tumour ADC may be useful
clinically to detect treatment response. Treatment response
should be detectable early in the course of therapy since
ADC increased more than 50% even for a dose which pro-
duced no decrease in tumour volume and modest cell kill (i.e.
the TGD of 4.3 days observed for 150 mg kg-' CP corres-
ponds to roughly 50% cell kill, assuming the tumour regrows
at the same rate after treatment; Corbett and Valeriote,
1987). If the changes in ADC observed in this study are
evident for other commonly used anti-cancer treatments in
different tumour types and specific to a therapeutic response,
this approach should be broadly applicable as a response
predictor.
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